Abstract
Background:
Selecting the appropriate patient for further treatment after surgery for gastric cancer can improve the patient prognosis. Circulating tumor DNA (ctDNA) has the potential to predict recurrence and prognosis after gastric cancer surgery, but the results are still inconclusive. As the completed studies had small sample sizes and were inconsistent, a meta-analysis was conducted to assess the effect of ctDNA on recurrence and prognosis after gastric cancer surgery.
Methods:
PubMed, Embase, Scopus, and the Web of Science were searched for potentially eligible studies published up to April 7, 2023. Pooled relative risk (RR) and pooled hazard ratio (HR) were calculated to evaluate recurrence, recurrence-free survival (RFS), and overall survival (OS) following gastric cancer surgery.
Results:
A pooled analysis revealed that patients who were ctDNA positive before and after surgery were at a high risk of gastric cancer recurrence (RR = 1.79, 95% CI: 1.19–2.71; RR = 3.17, 95% CI: 2.36–4.25). The pooled data revealed that ctDNA-positive patients had a poorer RFS and OS (HR = 6.37, 95% CI: 2.70–15.01; HR = 4.58, 95% CI: 1.68–12.49).
Conclusions:
ctDNA-positive patients were at a high risk of recurrence after gastric cancer surgery and had a poorer prognosis. Hence, ctDNA-positive patients needed close follow-up and further treatment.
Keywords: circulating tumor DNA, gastric cancer, meta-analysis, prognosis, recurrence
1. Introduction
Gastric cancer has the fifth-highest incidence rate and mortality rate in the world, causing 782,685 cancer deaths each year and posing a serious health risk.[1] Despite the rapid development of new treatments, perioperative chemotherapy and radical surgery remain the mainstays of localized gastric cancer treatment.[2] Despite localized gastric cancer undergoing curative gastrectomy, the recurrence rate of gastric cancer was 43% at 2 years and up to 85% at 5 years after surgery, and most gastric cancer recurrences were already in the progressive stage with no chance of cure.[3] Only 3.2% of patients with recurrent gastric cancer received potentially curative treatment.[4] Molecular residual disease (MRD) is the main cause of the recurrence of gastric cancer after surgery. The sensitivity of clinical imaging and tumor markers for postoperative MRD in gastric cancer was low, with carcinoembryonic antigen and carbohydrate antigen 19-9 having a sensitivity of only 34% and 24%, respectively, in diagnosing postoperative recurrence of gastric cancer.[5] In addition, contrast-enhanced computed tomography (CT) was the most commonly used imaging method to detect recurrence of gastric cancer, with a sensitivity of only 70%–73%.[6] Therefore, there is an urgent need for highly accurate biomarkers to detect recurrence of gastric cancer in clinical practice so that patients with recurrence can receive timely treatment and ultimately improve their survival.[7,8]
Circulating tumor DNA (ctDNA) is a fragment of DNA that is released into the bloodstream when a tumor undergoes necrosis or apoptosis.[9] ctDNA contains complete information on tumor variation and has developed rapidly in recent years for guiding tumor treatment and monitoring treatment outcome and prognosis.[10–12] The concentration of ctDNA in the blood is very low and accounts for approximately 0.01%–2% of cell-free DNA (cfDNA), where cfDNA is derived from white blood cells and consists of double-stranded DNA fragments of approximately 140 to 170 base pairs (bp) in length and ctDNA usually consists of < 145 bp in length. Moreover, previous biotechnologies had low sensitivity for detecting ctDNA.[13,14] The sensitivity of ctDNA testing has gradually improved with the development of molecular biology techniques, particularly next-generation sequencing and droplet digital PCR and cancer personalized profiling by deep sequencing and tagged-amplicon deep sequencing, etc.[9,15] ctDNA as part of a liquid biopsy has the advantage of being noninvasive and easily sampled multiple times. Additionally, ctDNA can detect tumor variation even when tumor tissue is not available and can avoid tumor tissue heterogeneity in biopsies.[16] ctDNA has been shown to detect the recurrence of breast, lung, colon, and bladder cancers after surgery.[17–21] Although several studies have explored ctDNA as a predictor of recurrence of gastric cancer after surgery in recent years, the current studies suffer from small sample sizes and inconsistent or even opposite results.[22–29] We will use meta-analysis to explore ctDNA ability to predict recurrence of gastric cancer after surgery and provide new evidence for the clinical application of ctDNA in gastric cancer. The primary aim of the study was to assess ctDNA to predict the recurrence of operable gastric cancer. A secondary aim was to use ctDNA to assess the prognosis of gastric cancer.
2. Methods
2.1. Literature search
This meta-analysis was carried out according to the preferred reporting items for systematic reviews and meta-analyses guidelines and the meta-analysis of observational studies in epidemiology.[30,31] See Supplementary Appendices 1, http://links.lww.com/MD/K793 and 2, http://links.lww.com/MD/K794. With a search deadline of April 7, 2023, we searched PubMed, Embase, Scopus, and Web of Science for studies on ctDNA predicting recurrence risk and assessing prognosis in operable gastric cancer patients. Supplementary Appendix 3, http://links.lww.com/MD/K795 provides a detailed procedure. Based on the inclusion and exclusion criteria, 2 investigators (Mi, Li) independently screened studies from the database, extracted and entered relevant eligible studies, and in the event of disagreement, the final outcome was determined by adding a third person (Wang) to the discussion. Papers that were plainly irrelevant to the study were excluded by reading the title and abstract in accordance with the inclusion and exclusion criteria, and the full text of the remaining papers was read to determine if they were eventually included. The process of retrieval in this study was not limited by language. The study search technique included a combination of subject terms and free words, and it was as follows: (Minimal residual disease OR Recurrence OR Prognosis OR MRD OR Neoplasm recurrence) AND (Gastric Cancer OR Stomach Neoplasms OR Stomach cancer OR Stomach tumor OR Gastric tumor) AND (“Tumor DNA AND Cell-Free” OR “Cell-Free Tumor AND DNA” OR Cell Free Tumor DNA OR “Tumor DNA AND Circulating” OR “Circulating Tumor AND DNA” OR ctDNA OR Circulating Tumor DNA). In addition, to avoid omissions, the investigators looked for references in the included study.
2.2. Selection and exclusion criteria
The inclusion criteria were as follows: patients were diagnosed with operable gastric cancer; investigation of the role of ctDNA in the prediction of tumor recurrence risk and assessment of prognosis; studies that provided enough information to calculate the RR for predicting tumor recurrence and HR for assessment of prognosis; and human clinical trial studies. The following were the exclusion criteria: meta-analysis, reviews, and letters; studies for which relevant raw data were not available; studies involving co-morbidities with other malignant diseases; studies involving gastrooesophageal cancer; and studies detecting cfDNA.
2.3. Data extraction and quality assessment
Two investigators (Han, Wang) independently collected data for each included study by developing a data extraction form, and if the comparison of the extracted data did not agree, the disagreement was resolved by consulting a third person (Ma). For the risk of tumor recurrence, the number of ctDNA-positive patients and the number of ctDNA-negative patients were extracted. Regarding the prognostic indicators overall survival (OS) and recurrence-free survival (RFS), hazard ratio (HR) as well as 95% confidence intervals (95% CI) were extracted for each study. The setting of ctDNA positivity thresholds for each included study was derived from the original study. If the relevant data is not available from the original study, we will contact the corresponding author of the original study to obtain the raw data.
The data extract also included the following basic information: first author, year of publication, country, patient count, average age, gender, number of serum samples, sample type, testing methods, number of genes, number of centers, study design, TNM staging, clinical stage, median follow-up, ctDNA testing time, definition of the positive ctDNA, and treatment strategy. In addition, data related to ctDNA shedding for different types of gastric cancer were also extracted. We used the Newcastle-Ottawa scale to rate the included studies from 0 to 9 based on the content of the included studies and the scale judgement criteria. A total of 20 entries in the Reporting Recommendations for Tumor Marker Prognostic Studies list contain an introduction, materials, methods, results, and discussion that were used to assess the quality of the included studies.
2.4. Statistical analysis
The effect sizes for risk of tumor recurrence were assessed by the Mantel Haenszel method as relative risk (RR) and 95% CI, and for prognosis as HR and their 95% CI for OS and RFS. To gain a thorough understanding of ctDNA role in predicting the prognosis of gastric cancer, we evaluated the baseline preoperative and postoperative RFS and OS. To assess the extent of heterogeneity among the included studies, we utilized a Chi-squared Q test and I2 coefficients. A statistically significant difference was considered at P < .05, employing a random effects model. In addition, we performed sensitivity analyses to test the stability of the meta-analysis results, and finally, the egger test and harbor test were used to assess whether there was publication bias in this study. The overall effect test was statistically significant at P < .05, and STATA 17.0 software was used to conduct all analyses.
3. Results
3.1. Search results
An initial selection of 2058 articles was achieved after careful searching of the databases according to the search strategy that had been developed. After 799 duplicate articles were removed, 1234 irrelevant articles were excluded after careful reading of the titles and abstracts. After conducting a thorough in-depth review of the full-text articles, we excluded 17 studies. These exclusions encompassed articles related to gastroesophageal cancer, correspondence, cfDNA, reviews, and studies lacking original data. The final meta-analysis included 8 studies with a total of 423 patients, as detailed in Figure 1.
Figure 1.
Literature search and study selection flow diagram for systematic reviews.
3.2. Characteristics of eligible studies and quality assessment
A total of 423 patients and 884 serum samples were included in the meta-analysis of 8 studies published between 2019 and 2022, in which the study characteristics and demographics are summarized in Table 1. The timing of ctDNA testing, the definition of positive ctDNA, and treatment strategies were summarized in Supplementary Appendix 4, http://links.lww.com/MD/K796. Supplementary Appendix 5, http://links.lww.com/MD/K797 provided a comparison of ctDNA shedding according to gastric cancer type, different stages, localization, pathological response, and degree of differentiation. The results of the assessment of the quality of the included studies by means of the Newcastle-Ottawa scale, which includes 3 subsets of selection comparability and outcome, are shown in Supplementary Appendix 6, http://links.lww.com/MD/K798. The quality assessment of the included studies showed that the included studies were of high quality, which was also confirmed by the Reporting Recommendations for Tumor Marker Prognostic Studies checklist in Supplementary Appendix 7, http://links.lww.com/MD/K799.
Table 1.
Characteristics of the included studies in this meta-analysis.
| First author | Kim | Cabel | Yang | Leal | Suzuki | Fedyanin | Huffman | Yuan |
|---|---|---|---|---|---|---|---|---|
| Publication (yr) | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2022 | 2022 |
| Country | Korea | France | China | USA | Japan | Russia | USA | China |
| Patients (n) | 19 | 19 | 46 | 50 | 46 | 42 | 88 | 100 |
| Mean age (range/IQR) | 60 (41–77) | 62 (45–78) | 54 (28–78) | 60 (30–77) | 72 (46–92) | NA | NA | NA |
| Male (%) | 88 | 84 | 83 | 72 | 76 | NA | NA | NA |
| Serum samples (n) | 107 | 50 | 296 | 120 | 40 | NA | 271 | NA |
| Sample type | Plasma | Plasma | Plasma | Plasma | Plasma | Plasma | Plasma | Plasma |
| Tissue testing methods | WGS | NGS | NGS | NA | NA | NGS | WES | NGS |
| ctDNA testing methods | PCR | ddPCR | NGS | NGS | ddPCR | ddPCR | NGS | NA |
| Tissue tumor oncogenes (n) | NA | 39 | 1021 | NA | NA | 50 | NA | 425 |
| ctDNA oncogenes (n) | NA | 5 | 50 | 58 | 52 | NA | NA | NA |
| Post-operative ctDNA testing time | < 12 mo | <1 mo | 9–48 d | 6.5 wk | 7.3 d | 7 d | 16 wk | 4 d |
| The time ahead for clinical detection | 4.05 mo | NA | 6 mo | 8.9 mo | 6 mo | NA | NA | NA |
| Centers (n) | Multicentre | Single center | Single center | Multicentre | Multicentre | NA | Multicentre | NA |
| Study design | Retrospectively | Prospectively | Prospectively | Retrospectively | Prospectively | Prospectively | Retrospectively | Prospectively |
| Clinicalstage | II-IV | NA | I-III | IA-IV | II-III | I-IV | I-III | II-III |
| TNM staging | T3-T4b/N0-N3b/M0 | T1-T4/N0-N+ | pT1a-pT4a/pN0-pN3b/pM0 | ypT0-ypT4b/ypN0-ypN3b/ypM0-ypM1 | NA | NA | NA | NA |
| Median follow-up (range/IQR, mo) | 12 | 26 (11–35) | 29.1 (5.7–32.3) | 42 | 12.2 | NA | 34.8 | NA |
dd PCR = droplet digital polymerase chain reaction, IQR = interquartile range, n = number, NA = not available, NGS = next-generation sequencing, PCR = polymerase chain reaction, WES = whole-exome sequencing, WGS = whole-genome sequencing.
3.3. Preoperative ctDNA predicts the risk of gastric cancer recurrence
A total of 3 studies were included in the pooled analysis of preoperative ctDNA to predict the risk of recurrence of gastric cancer.[22–24] The heterogeneity of preoperative ctDNA predicting postoperative recurrence of gastric cancer was small, so we used a fixed effects model to calculate the combined RR as shown in Figure 2 (RR = 1.79, 95% CI: 1.19–2.71, P < .05; I2 = 0.0%, P > .05). Preoperative ctDNA positivity was associated with a higher risk of gastric cancer recurrence in postoperative patients with gastric cancer. The 3 studies included in the pooled analysis showed inconsistent results, with Kim study and Yang study showing that although there was a tendency for preoperative ctDNA positivity to be associated with greater tumor recurrence, the results did not reach statistical significance, possibly due to the small sample sizes included in these 2 studies.[22,24] However, Leal study showed that pre-operative ctDNA positive patients have a higher risk of recurrence of gastric cancer (RR = 2.08, 95% CI: 1.20–3.58).[23]
Figure 2.
A forest plot of the pooled effect for relative risk in presurgical ctDNA prediction of gastric cancer recurrence after surgery. ctDNA = circulating tumor DNA.
3.4. Postoperative ctDNA predicts the risk of gastric cancer recurrence after surgery
A total of 8 studies were included in the pooled analysis of postoperative ctDNA to predict the risk of tumor recurrence after surgery.[22–29] To fully explore the postoperative ctDNA prediction of postoperative tumor recurrence, we used a random-effects model and a fixed-effects model to calculate the combined RR as shown in Figure 3 and Supplementary Appendix 8, http://links.lww.com/MD/K800, respectively. Postoperative ctDNA-positive patients had a higher risk of tumor recurrence, with a pooled RR of 3.17, 95% CI:2.36–4.25 and 3.68, 95% CI:2.66–5.09) for both the random-effects and fixed-effects models, respectively. Although both statistical models showed that postoperative ctDNA was a good predictor of postoperative gastric cancer recurrence, the results of the random-effects model were more conservative and reliable than the fixed-effects model. The 8 studies included in the pooled analysis showed inconsistent results, with the Cabel and Suzuki studies showing that postoperative ctDNA positivity did not predict postoperative tumor recurrence, possibly due to the small sample sizes included in these 2 studies.
Figure 3.
A forest plot of the pooled effect for relative risk in the prediction of gastric cancer recurrence after surgery using post-surgical ctDNA. ctDNA = circulating tumor DNA.
3.5. Prediction of RFS by ctDNA
A total of 6 studies were included in the pooled analysis of ctDNA for predicting postoperative RFS in gastric cancer.[22,23,26–29] In the pooled analysis, Leal study and Fedyanin study were included separately for different time points of ctDNA testing.[23,29] The heterogeneity of ctDNA in predicting postoperative RFS in gastric cancer was large, so we used a random effects model to calculate the pooled HR in Figure 4 (HR = 6.37, 95% CI: 2.70–15.01, P < .05; I2 = 67%, P < .05). The high heterogeneity may be due to the different methods used to detect ctDNA and the different demographics of the included studies. Regarding prognosis after surgery for gastric cancer ctDNA-positive patients have worse RFS. Only one study of ctDNA testing at baseline showed that baseline testing of ctDNA was not associated with RFS after gastric cancer surgery.[23] However, pooled results showed that preoperative ctDNA-positive patients had a worse RFS (HR = 2.67, 95% CI: 1.20–5.95).[23,29] Although postoperative ctDNA yielded inconclusive results in predicting RFS, a pooled analysis revealed that postoperative ctDNA positive patients had a worse RFS (HR = 14.09, 95% CI: 7.31–27.15).
Figure 4.
Forest plot on ctDNA prediction of recurrence-free survival with a pooled effect hazard ratio. ctDNA = circulating tumor DNA.
3.6. Prediction of OS by ctDNA
A total of 3 studies were included in the pooled analysis of ctDNA predicting OS in patients with postoperative gastric cancer.[22,23,27] The different time points for ctDNA testing in Leal study were included separately in the pooled analysis. The heterogeneity of ctDNA in predicting postoperative OS in gastric cancer was large, so we used a random effects model to calculate the pooled HR in Figure 5. The high heterogeneity may be due to the different methods used to detect ctDNA and the different follow-up times. Pooled analysis showed ctDNA-positive patients had worse OS (HR = 4.58, 95%CI: 1.68–12.49, P < .05; I2 = 68.4%, P < .05). Leald study showed that baseline ctDNA testing was not associated with OS after surgery for gastric cancer, but preoperative ctDNA positive patients had worse OS (HR = 2.7 95% CI: 1.09–6.66). Additional pooled analysis showed that post-operative ctDNA positive patients had worse OS (HR = 11.78, 95% CI: 4.40–31.53).
Figure 5.
Forest plot on ctDNA prediction of overall survival with a pooled effect hazard ratio. ctDNA = circulating tumor DNA.
3.7. Publication bias and sensitivity analysis
The egger test and harbor test were used to assess publication bias, and the results showed no significant publication bias (P = .876 and P = .426) in Supplementary appendix 9, http://links.lww.com/MD/K801 and Supplementary appendix 10, http://links.lww.com/MD/K802. Sensitivity analyses were used to examine the effect of individual studies on the stability of the pooled ctDNA for predicting the risk of tumor recurrence, and the pooled RRs and 95% CIs after sequential removal of each study indicated that none of the studies could significantly affect the pooled effect (see Supplementary Appendix 11, http://links.lww.com/MD/K803).
4. Discussion
Early detection of postoperative recurrence in patients with gastric cancer can facilitate timely adjustment of treatment plans and have a positive impact on improving the prognosis of patients. For those at high risk of tumor recurrence, multimodal treatment, including radiotherapy, and individualized follow-up should be undertaken. Most recurrences of gastric cancer are diagnosed in the advanced stage, and the lack of effective treatment in the advanced stage contributes to the high mortality rate of gastric cancer.[32] In addition, despite the use of multimodal treatment for gastric cancer, the recurrence rate after surgery is high, and most gastric cancer patients experience local recurrence, peritoneal metastases, and distant metastases after surgery.[33,34] The risk of recurrence after surgery for gastric cancer is now mainly assessed by the pathological staging and tumor regression grading system, but its application in clinical practice is somewhat limited.[4,35,36] In addition, the sensitivity of current imaging and tumor markers for monitoring recurrence of gastric cancer is insufficient, so there is an urgent clinical need for a biomarker that can accurately monitor recurrence of gastric cancer after surgery. ctDNA derived from necrotic or apoptotic tumor cell DNA fragments with oncogene variants shows promise in predicting tumor recurrence after surgery. This study showed that pre- and postoperatively positive ctDNA patients had a higher risk of postoperative recurrence of gastric cancer (RR = 1.79, RR = 3.17), as well as a worse FRS (HR = 6.37) and worse OS (HR = 4.58).
Gastric cancer is a very heterogeneous malignancy, and studies have shown that not all types of gastric cancer can detect ctDNA shedding; the current preoperative detection rate of ctDNA is about 30%–50%.[37–40] For ctDNA non-shedders, ctDNA remained negative even after postoperative tumor recurrence, suggesting that ctDNA surveillance for postoperative recurrence of gastric cancer may not be appropriate for patients with ctDNA non-shedders.[24] One of the obstacles to the clinical use of ctDNA is the cost of testing, especially with next-generation sequencing and whole-genome sequencing. Post-operative detection of tumor recurrence in gastric cancer with ctDNA shedding facilitates improved cost-effectiveness. Identifying the type of gastric cancer that has ctDNA shedding facilitates the selection of suitable gastric cancer patients to be monitored for recurrence after gastric cancer surgery. Yang study found that worse clinical stage, worse N stage, worse T stage, or cardiac gastric cancer had higher preoperative ctDNA shedding. In addition, only the worse T stage had significantly higher preoperative ctDNA shedding in the multivariate analysis.[22] Leal study then showed that ctDNA was more likely to be detected preoperatively in patients with intestinal subtypes than in patients with diffuse subtypes.[23] Cabel study indicated that ctDNA shedders were not associated with Lauren classification, and in short, different studies have shown inconsistent or even opposite results for pre-operative ctDNA shedding in gastric cancer.[25] In addition, the published studies had small sample sizes, so further large multicentre studies are needed to identify which types of gastric cancer have preoperative ctDNA shedding.
Many studies have explored ctDNA as a predictor of post-operative recurrence in solid tumors, where ctDNA has become a biomarker of tumor recurrence in breast, lung, and colon cancers.[17–19,21] There is currently a small amount of evidence for the use of ctDNA in predicting recurrence of gastric cancer after surgery, and we have shown by meta-analysis that patients with preoperatively positive ctDNA have a higher risk of gastric cancer recurrence after surgery. Inconsistent results were found in the pooled analyses, with Kim study and Yang study showing that although there was a tendency for preoperative ctDNA positivity to be associated with greater tumor recurrence, the results did not reach statistical significance.[22,24] The possible reason for this was that the sample sizes of the 2 studies were small, with Kim study and Yang study having a sample size of 17 and 40, respectively. Leal study then showed that preoperative ctDNA-positive patients had a higher risk of postoperative gastric cancer recurrence.[23] Patients in Leal study received preoperative chemotherapy, and the detection of ctDNA prior to surgery is indicative of a suboptimal response to preoperative chemotherapy in this group.[23] Given that preoperative ctDNA-positive patients have a higher risk of recurrence of gastric cancer, more aggressive surgical treatment and intensive postoperative chemotherapy should be chosen for this group of patients. This pooled analysis on the assessment of preoperative ctDNA to predict the risk of recurrence of gastric cancer included a few studies and a small sample size, and the conclusions still need to be confirmed by a large sample of multicentre studies.
The study showed through a meta-analysis that post-operative ctDNA positive patients have a higher risk of recurrence of gastric cancer after surgery. ctDNA had the following advantages as a liquid biopsy to predict recurrence of gastric cancer after surgery. Firstly, ctDNA predicted recurrence of gastric cancer 6 months earlier than radiographic recurrence and 4 to 8.9 months earlier than clinical recurrence.[22–24] Secondly, the emergence of new tumor genetic variants during and after chemotherapy, especially new driver gene mutations, suggests that ctDNA can detect new tumor genetic variants in time for individualized and precise treatment, and this is another advantage of ctDNA independent of pre-operative tissue genotyping.[22] Serial monitoring of post-operative ctDNA has been shown to increase the sensitivity of detecting tumor recurrence compared to a single post-operative ctDNA test in colon and breast cancer studies.[19,21,41] Yang study also showed that serial monitoring of ctDNA is more likely to detect recurrence of post-operative gastric cancer, so more frequent screening of post-operative ctDNA is beneficial in detecting recurrence of post-operative gastric cancer.[22] In addition, ctDNA was not always positive after surgery for gastric cancer in the postoperative follow-up. Some patients became negative for ctDNA 1 month after surgery and then turned positive again before tumor recurrence, indicating that ctDNA levels and ctDNA dynamics correlated in the postoperative follow-up.[24] However, Cabel study showed that ctDNA did not predict recurrence of gastric cancer after surgery, which is inconsistent with other studies probably because Cabel study tested ctDNA at a low level of 20%, 0% and 8% at baseline preoperatively and postoperatively, respectively. In addition, in Cabel study, ctDNA levels decreased significantly after preoperative FOLFOX-based chemotherapy, so that ctDNA was not detectable in any of the preoperative patients.[25] Similar ctDNA kinetics results were observed in breast and rectal cancers.[42,43] In conclusion, individualized treatment and follow-up plans based on risk factors for recurrence can reduce recurrence and metastasis rates in patients with gastric cancer and improve their survival rates. In addition, ctDNA-guided categorical therapy for colon cancer has reduced adjuvant chemotherapy[44] Future research should look at whether ctDNA can identify recurrence after postoperative chemotherapy for gastric cancer, and whether ctDNA can guide postoperative chemotherapy. As published studies have shown, ctDNA has great potential for clinical application in predicting tumor recurrence and prognosis in operable gastric cancer, and several related studies are already in progress (NCT05029869, NCT03957564, and NCT04576858).
Although the first meta-analysis demonstrated the potential usefulness of ctDNA in predicting tumor recurrence and prognosis in gastric cancer, it is important to acknowledge the following limitations. Firstly, the number of studies and sample size included in this meta-analysis were relatively small. Secondly, the meta-analysis did not include subgroup analysis because of the small number of studies included. Thirdly, there was heterogeneity in the meta-analysis. Fourth, the Suzuki study included in the pooled analysis for RFS included a proportion of patients with colon cancer. Finally, it worth noting that many of the studies included in the prognosis assessment had relatively short follow-up periods, especially for assessing OS, which may not have been long enough to draw definitive conclusions.
5. Conclusion
In conclusion, this study showed a higher risk of gastric cancer recurrence in ctDNA-positive patients at presurgery and postsurgery, suggesting that these patients may respond poorly to treatment and should be closely followed. ctDNA could also be used to predict gastric cancer prognosis, with ctDNA-positive patients having a worse OS and a worse RFS.
Author contributions
Conceptualization: Junjie Mi.
Data curation: Ruijun Ma.
Formal analysis: Junjie Mi, Ruijun Ma.
Investigation: Huiying Li.
Methodology: Rong Wang.
Software: Xiaofang Han.
Supplementary Material
Abbreviations:
- cfDNA
- cell-free DNA
- CT
- computed tomography
- ctDNA
- circulating tumor DNA
- HR
- hazard ratio
- MRD
- molecular residual disease
- OS
- overall survival
- RFS
- recurrence-free survival
- RR
- relative risk
- WGS
- whole-genome sequencing
Supplemental Digital Content is available for this article.
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
The study was a systematic review that did not require ethics committee approval.
The authors have no funding and conflicts of interest to disclose.
How to cite this article: Mi J, Wang R, Han X, Ma R, Li H. Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis. Medicine 2023;102:48(e36228).
References
- [1].Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [DOI] [PubMed] [Google Scholar]
- [2].Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Youn HG, An JY, Choi MG, et al. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol. 2010;17:448–54. [DOI] [PubMed] [Google Scholar]
- [4].Baiocchi GL, Marrelli D, Verlato G, et al. Follow-up after gastrectomy for cancer: an appraisal of the Italian research group for gastric cancer. Ann Surg Oncol. 2014;21:2005–11. [DOI] [PubMed] [Google Scholar]
- [5].Shibata C, Nakano T, Yasumoto A, et al. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer. BMC Surg. 2022;22:213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Li CF, Zheng J, Xue YW. The value of contrast-enhanced computed tomography in predicting gastric cancer recurrence and metastasis. Cancer Biomark. 2017;19:327–33. [DOI] [PubMed] [Google Scholar]
- [7].D’Ugo D, Biondi A, Tufo A, et al. Follow-up: the evidence. Dig Surg. 2013;30:159–68. [DOI] [PubMed] [Google Scholar]
- [8].Huang SM, Chen YC, Chen WY, et al. Optimal timing for postsurgical adjuvant therapy in patients with gastric cancer: a propensity score matching study. J Cancer. 2019;10:332–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening. Cancers (Basel). 2021;13:3600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30:1472–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Sabari JK, Offin M, Stephens D, et al. A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers. J Natl Cancer Inst. 2019;111:575–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Mi J, Han X, Wang R, et al. Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: a meta-analysis. Eur J Clin Invest. 2022;52:e13842. [DOI] [PubMed] [Google Scholar]
- [13].Bryzgunova OE, Konoshenko MY, Laktionov PP. Concentration of cell-free DNA in different tumor types. Expert Rev Mol Diagn. 2021;21:63–75. [DOI] [PubMed] [Google Scholar]
- [14].Tivey A, Church M, Rothwell D, et al. Circulating tumour DNA - looking beyond the blood. Nat Rev Clin Oncol. 2022;19:600–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].Chan KC, Jiang P, Chan CW, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A. 2013;110:18761–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48. [DOI] [PubMed] [Google Scholar]
- [17].Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394–403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [19].Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133. [DOI] [PubMed] [Google Scholar]
- [20].McDonald BR, Contente-Cuomo T, Sammut SJ, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019;11:eaax7392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [21].Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [22].Yang J, Gong Y, Lam VK, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020;11:346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [23].Leal A, van Grieken NCT, Palsgrove DN, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11:525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [24].Kim YW, Kim YH, Song Y, et al. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer. Exp Mol Med. 2019;51:1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [25].Cabel L, Decraene C, Bieche I, et al. Limited sensitivity of circulating tumor DNA detection by droplet digital PCR in non-metastatic operable gastric cancer patients. Cancers (Basel). 2019;11:396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [26].Suzuki T, Suzuki T, Yoshimura Y, et al. Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers. Oncotarget. 2020;11:3198–207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [27].Yuan SQ, Huang YS, Nie RC, et al. Circulating tumor DNA and recurrence risk in stage II-III gastric cancer. J Clin Oncol. 2022;40:4054–4054. [Google Scholar]
- [28].Huffman BM, Aushev VN, Budde GL, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precision Oncol. 2022;6:e2200420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [29].Fedyanin M, Ignatova E, Boyarskikh U, et al. Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC). Ann Oncol. 2020;31:S1295. [Google Scholar]
- [30].Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [31].Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008–12. [DOI] [PubMed] [Google Scholar]
- [32].Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388:2654–64. [DOI] [PubMed] [Google Scholar]
- [33].Bickenbach KA, Gonen M, Strong V, et al. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–8. [DOI] [PubMed] [Google Scholar]
- [34].Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49. [DOI] [PubMed] [Google Scholar]
- [35].Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch. 2018;472:175–86. [DOI] [PubMed] [Google Scholar]
- [36].Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. 2016;34:2721–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [37].Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [38].Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [39].Fang WL, Lan YT, Huang KH, et al. Clinical significance of circulating plasma DNA in gastric cancer. Int J Cancer. 2016;138:2974–83. [DOI] [PubMed] [Google Scholar]
- [40].Hamakawa T, Kukita Y, Kurokawa Y, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer. 2015;112:352–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [41].Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7:1034–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [42].Tie J, Cohen JD, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;68:663–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [43].Riva F, Bidard FC, Houy A, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem. 2017;63:691–9. [DOI] [PubMed] [Google Scholar]
- [44].Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in Stage II colon cancer. N Engl J Med. 2022;386:2261–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.